Patent classifications
A61K31/4525
Pharmaceutical compositions
An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.
Pharmaceutical compositions
An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.
Pharmaceutical compositions
An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.
USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASE
The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMAs) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) through reduced cell and blood concentration of ceramides.
USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASE
The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMAs) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) through reduced cell and blood concentration of ceramides.
INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE
The present invention provides a novel use of a compound having a plasminogen activator inhibitor-1 (PAI-1) inhibitory effect. Specifically, a compound having a PAI-1 inhibitory effect is used as an intranostimulator, an immune checkpoint inhibitor, an inhibitor for exacerbation of tumor cells caused by PD-L1, or an enhancer of immunotherapy for tumors, based on the inhibitory effect of the compound on expression induction of immune checkpoint molecules.
INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE
The present invention provides a novel use of a compound having a plasminogen activator inhibitor-1 (PAI-1) inhibitory effect. Specifically, a compound having a PAI-1 inhibitory effect is used as an intranostimulator, an immune checkpoint inhibitor, an inhibitor for exacerbation of tumor cells caused by PD-L1, or an enhancer of immunotherapy for tumors, based on the inhibitory effect of the compound on expression induction of immune checkpoint molecules.
Therapeutical methods, formulations and nutraceutical formulations
Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.
Therapeutical methods, formulations and nutraceutical formulations
Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.
Therapeutical methods, formulations and nutraceutical formulations
Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.